Identification of serum metabolites associated with risk of type 2 diabetes using a targeted metabolomic approach

Diabetes

Volumn 62, Issue 2, 2013, Pages 639-648

  Floegel, Anna ^a   Stefan, Norbert ^b   Yu, Zhonghao ^c   Mühlenbruch, Kristin ^a   Drogan, Dagmar ^a   Joost, Hans Georg ^a   Fritsche, Andreas ^b   Häring, Hans Ulrich ^b   De Angelis, Martin Hrabě ^c   Peters, Annette ^c   Roden, Michael ^d,e   Prehn, Cornelia ^c   Wang Sattler, Rui ^c   Illig, Thomas ^c,f   Schulze, Matthias B ^a   Adamski, Jerzy ^c   Boeing, Heiner ^a   Pischon, Tobias ^a,g  

^a GERMAN INSTITUTE OF HUMAN NUTRITION   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c INSTITUTE OF EPIDEMIOLOGY   (Germany)

^d HEINRICH HEINE UNIVERSITY   (Germany)

^e University Clinic   (Germany)

^f HANNOVER MEDICAL SCHOOL   (Germany)

^g MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACYL ALKYL PHOSPHATIDYLCHOLINE; ACYLCARNITINE; GLYCINE; HEXOSE; LYSOPHOSPHATIDYLCHOLINE; PHENYLALANINE; PHOSPHATIDYLCHOLINE; PHOSPHOLIPID; SPHINGOMYELIN PHOSPHODIESTERASE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; FLOW INJECTION ANALYSIS; FOLLOW UP; HUMAN; INSULIN RELEASE; INSULIN SENSITIVITY; MAJOR CLINICAL STUDY; MALE; METABOLITE; METABOLOMICS; NON INSULIN DEPENDENT DIABETES MELLITUS; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; TANDEM MASS SPECTROMETRY;

ADULT; BIOLOGICAL MARKERS; DIABETES MELLITUS, TYPE 2; FEMALE; GLYCINE; HEXOSES; HUMANS; INSULIN; INSULIN RESISTANCE; MALE; METABOLOMICS; MIDDLE AGED; PHENYLALANINE; PHOSPHATIDYLCHOLINES; RISK; SERUM; SPHINGOMYELINS;

EID: 84873042769     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db12-0495     Document Type: Article

References (56)

1. DeFronzo RA. Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 2009;58:773-795
2. Peters AL, Davidson MB, Schriger DL, Hasselblad V; Meta-analysis Research Group on the Diagnosis of Diabetes Using Glycated Hemoglobin Levels. A clinical approach for the diagnosis of diabetes mellitus: an analysis using glycosylated hemoglobin levels. JAMA 1996;276:1246-1252
3. Herder C, Baumert J, Zierer A, et al. Immunological and cardiometabolic risk factors in the prediction of type 2 diabetes and coronary events: MONICA/KORA Augsburg case-cohort study. PLoS ONE 2011;6:e19852
4. Abu-Qamar M, Wilson A. Evidence-based decision-making: the case for diabetes care. Int J Evid Based Healthc 2007;5:254-260
5. Swellam M, Sayed Mahmoud And M, Abdel-Fatah Ali A. Clinical implications of adiponectin and inflammatory biomarkers in type 2 diabetes mellitus. Dis Markers 2009;27:269-278
6. Li S, Shin HJ, Ding EL, van Dam RM. Adiponectin levels and risk of type 2 diabetes: a systematic review and meta-analysis. JAMA 2009;302:179-188
7. Ford ES, Schulze MB, Bergmann MM, Thamer C, Joost HG, Boeing H. Liver enzymes and incident diabetes: findings from the European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study. Diabetes Care 2008;31:1138-1143
8. Stefan N, Fritsche A, Weikert C, et al. Plasma fetuin-A levels and the risk of type 2 diabetes. Diabetes 2008;57:2762-2767
9. Bain JR, Stevens RD, Wenner BR, Ilkayeva O, Muoio DM, Newgard CB. Metabolomics applied to diabetes research: moving from information to knowledge. Diabetes 2009;58:2429-2443
10. Newgard CB, An J, Bain JR, et al. A branched-chain amino acid-related metabolic signature that differentiates obese and lean humans and contributes to insulin resistance. Cell Metab 2009;9:311-326
11. Wopereis S, Rubingh CM, van Erk MJ, et al. Metabolic profiling of the response to an oral glucose tolerance test detects subtle metabolic changes. PLoS ONE 2009;4:e4525
12. Fiehn O, Garvey WT, Newman JW, Lok KH, Hoppel CL, Adams SH. Plasma metabolomic profiles reflective of glucose homeostasis in non-diabetic and type 2 diabetic obese African-American women. PLoS ONE 2010;5:e15234
13. Suhre K, Meisinger C, Döring A, et al. Metabolic footprint of diabetes: a multiplatform metabolomics study in an epidemiological setting. PLoS ONE 2010;5:e13953
14. Adams SH, Hoppel CL, Lok KH, et al. Plasma acylcarnitine profiles suggest incomplete long-chain fatty acid beta-oxidation and altered tricarboxylic acid cycle activity in type 2 diabetic African-American women. J Nutr 2009; 139:1073-1081
15. Hu FB. Metabolic profiling of diabetes: from black-box epidemiology to systems epidemiology. Clin Chem 2011;57:1224-1226
16. Schulze MB, Hoffmann K, Boeing H, et al. An accurate risk score based on anthropometric, dietary, and lifestyle factors to predict the development of type 2 diabetes. Diabetes Care 2007;30:510-515
17. Boeing H, Korfmann A, Bergmann MM. Recruitment procedures of EPIC-Germany. European Investigation into Cancer and Nutrition. Ann Nutr Metab 1999;43:205-215
18. Kroke A, Bergmann MM, Lotze G, Jeckel A, Klipstein-Grobusch K, Boeing H. Measures of quality control in the German component of the EPIC study. European Prospective Investigation into Cancer and Nutrition. Ann Nutr Metab 1999;43:216-224
19. Boeing H, Wahrendorf J, Becker N. EPIC-Germany-a source for studies into diet and risk of chronic diseases. European Investigation into Cancer and Nutrition. Ann Nutr Metab 1999;43:195-204
20. Weikert C, Stefan N, Schulze MB, et al. Plasma fetuin-A levels and the risk of myocardial infarction and ischemic stroke. Circulation 2008;118:2555-2562
21. Montonen J, Drogan D, Joost HG, et al. Estimation of the contribution of biomarkers of different metabolic pathways to risk of type 2 diabetes. Eur J Epidemiol 2011;26:29-38
22. Bergmann MM, Bussas U, Boeing H. Follow-up procedures in EPIC-Germany-data quality aspects. European Prospective Investigation into Cancer and Nutrition. Ann Nutr Metab 1999;43:225-234
23. Schienkiewitz A, Schulze MB, Hoffmann K, Kroke A, Boeing H. Body mass index history and risk of type 2 diabetes: results from the European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study. Am J Clin Nutr 2006;84:427-433
24. Rothman KJ, Greenland S, Lash TL. Case-control studies. In Modern epidemiology. 3rd ed. Rothman KJ, Greenland S, Eds. Philadelphia, Lippin-cott-Williams & Wilkins, 2008, p. 111-127
25. Meisinger C, Strassburger K, Heier M, et al. Prevalence of undiagnosed diabetes and impaired glucose regulation in 35-59-year-old individuals in Southern Germany: the KORA F4 Study. Diabet Med 2010;27:360-362
26. Rathmann W, Strassburger K, Heier M, et al. Incidence of type 2 diabetes in the elderly German population and the effect of clinical and lifestyle risk factors: KORA S4/F4 cohort study. Diabet Med 2009;26:1212-1219
27. Kowall B, Rathmann W, Strassburger K, Meisinger C, Holle R, Mielck A. Socioeconomic status is not associated with type 2 diabetes incidence in an elderly population in Germany: KORA S4/F4 cohort study. J Epidemiol Community Health 2011;65:606-612
28. Stefan N, Kantartzis K, Machann J, et al. Identification and characterization of metabolically benign obesity in humans. Arch Intern Med 2008;168: 1609-1616
29. Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 1999;22:1462-1470
30. Römisch-Margl W, Prehn C, Bogumil R, Röhring C, Suhre K, Adamski J. Procedure for tissue sample preparation and metabolite extraction for high throughput targeted metabolomics. Metabolomics 11 March 2011 [Epub ahead of print]
31. Floegel A, Drogan D, Wang-Sattler R, et al. Reliability of serum metabolite concentrations over a 4-month period using a targeted metabolomic approach. PLoS ONE 2011;6:e21103
32. Prentice RL. Design issues in cohort studies. Stat Methods Med Res 1995;4: 273-292
33. Holm S. A simple sequentially rejective multiple test procedure. Scand J Stat 1979;6:65-70
34. Hardy RJ, Thompson SG. Detecting and describing heterogeneity in meta-analysis. Stat Med 1998;17:841-856
35. Wang TJ, Larson MG, Vasan RS, et al. Metabolite profiles and the risk of developing diabetes. Nat Med 2011;17:448-453
36. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a non-parametric approach. Biometrics 1988;44:837-845
37. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-560
38. Hsieh FY, Lavori PW. Sample-size calculations for the Cox proportional hazards regression model with nonbinary covariates. Control Clin Trials 2000;21:552-560
39. Ruderman NB. Muscle amino acid metabolism and gluconeogenesis. Annu Rev Med 1975;26:245-258
40. Sekhar RV, McKay SV, Patel SG, et al. Glutathione synthesis is diminished in patients with uncontrolled diabetes and restored by dietary supplementation with cysteine and glycine. Diabetes Care 2011;34:162-167
41. Koves TR, Ussher JR, Noland RC, et al. Mitochondrial overload and incomplete fatty acid oxidation contribute to skeletal muscle insulin resistance. Cell Metab 2008;7:45-56
42. Muoio DM, Neufer PD. Lipid-induced mitochondrial stress and insulin action in muscle. Cell Metab 2012;15:595-605
43. Vianey-Liaud C, Divry P, Gregersen N, Mathieu M. The inborn errors of mitochondrial fatty acid oxidation. J Inherit Metab Dis 1987;10(Suppl 1): 159-200
44. She P, Van Horn C, Reid T, Hutson SM, Cooney RN, Lynch CJ. Obesity-related elevations in plasma leucine are associated with alterations in enzymes involved in branched-chain amino acid metabolism. Am J Physiol Endocrinol Metab 2007;293:E1552-E1563
45. Tremblay F, BrÛlé S, Hee Um S, et al. Identification of IRS-1 Ser-1101 as a target of S6K1 in nutrient-and obesity-induced insulin resistance. Proc Natl Acad Sci U S A 2007;104:14056-14061
46. Montonen J, Järvinen R, Knekt P, Heliövaara M, Reunanen A. Consumption of sweetened beverages and intakes of fructose and glucose predict type 2 diabetes occurrence. J Nutr 2007;137:1447-1454
47. Magnusson CD, Haraldsson GG. Ether lipids. Chem Phys Lipids 2011;164: 315-340
48. Cole LK, Vance JE, Vance DE. Phosphatidylcholine biosynthesis and li-poprotein metabolism. Biochim Biophys Acta 2012;182:754-761
49. Quehenberger O, Dennis EA. The human plasma lipidome. N Engl J Med 2011;365:1812-1823
50. Wallner S, Schmitz G. Plasmalogens the neglected regulatory and scavenging lipid species. Chem Phys Lipids 2011;164:573-589
51. Raubenheimer PJ, Nyirenda MJ, Walker BR. A choline-deficient diet exacerbates fatty liver but attenuates insulin resistance and glucose intolerance in mice fed a high-fat diet. Diabetes 2006;55:2015-2020
52. Jacobs RL, Devlin C, Tabas I, Vance DE. Targeted deletion of hepatic CTP: phosphocholine cytidylyltransferase alpha in mice decreases plasma high density and very low density lipoproteins. J Biol Chem 2004;279:47402-47410
53. Pietiläinen KH, Sysi-Aho M, Rissanen A, et al. Acquired obesity is associated with changes in the serum lipidomic profile independent of genetic effects-a monozygotic twin study. PLoS ONE 2007;2:e218
54. Kröger J, Zietemann V, Enzenbach C, et al. Erythrocyte membrane phos-pholipid fatty acids, desaturase activity, and dietary fatty acids in relation to risk of type 2 diabetes in the European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study. Am J Clin Nutr 2011;93:127-142
55. Rhee EP, Cheng S, Larson MG, et al. Lipid profiling identifies a tri-acylglycerol signature of insulin resistance and improves diabetes prediction in humans. J Clin Invest 2011;121:1402-1411
56. Yu Z, Kastenmüller G, He Y, et al. Differences between human plasma and serum metabolite profiles. PLoS ONE 2011;6:e21230